- Home
- RNA vs KRYS Comparison
RNA vs KRYS Comparison
Compare RNA & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- KRYS
- Stock Information
- Founded
- RNA 2012
- KRYS 2015
- Country
- RNA United States
- KRYS United States
- Employees
- RNA N/A
- KRYS N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNA Health Care
- KRYS Health Care
- Exchange
- RNA Nasdaq
- KRYS Nasdaq
- Market Cap
- RNA 4.4B
- KRYS 4.8B
- IPO Year
- RNA 2020
- KRYS 2017
- Fundamental
- Price
- RNA $32.74
- KRYS $168.58
- Analyst Decision
- RNA Strong Buy
- KRYS Strong Buy
- Analyst Count
- RNA 10
- KRYS 7
- Target Price
- RNA $63.60
- KRYS $206.67
- AVG Volume (30 Days)
- RNA 1.1M
- KRYS 243.7K
- Earning Date
- RNA 11-07-2024
- KRYS 11-04-2024
- Dividend Yield
- RNA N/A
- KRYS N/A
- EPS Growth
- RNA N/A
- KRYS N/A
- EPS
- RNA N/A
- KRYS 1.77
- Revenue
- RNA $10,117,000.00
- KRYS $241,519,000.00
- Revenue This Year
- RNA N/A
- KRYS $485.65
- Revenue Next Year
- RNA N/A
- KRYS $58.64
- P/E Ratio
- RNA N/A
- KRYS $95.31
- Revenue Growth
- RNA N/A
- KRYS 2722.80
- 52 Week Low
- RNA $8.37
- KRYS $107.50
- 52 Week High
- RNA $56.00
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- RNA 30.43
- KRYS 37.65
- Support Level
- RNA $32.04
- KRYS $162.33
- Resistance Level
- RNA $34.35
- KRYS $193.07
- Average True Range (ATR)
- RNA 2.07
- KRYS 8.51
- MACD
- RNA -0.55
- KRYS -2.74
- Stochastic Oscillator
- RNA 6.24
- KRYS 10.29
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.